BiotechTube
Minerva Biotechnologies

Minerva Biotechnologies

Waltham, United States· Est.
minervabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25.2M

Overview

Minerva Biotechnologies is a clinical-stage biotech targeting a foundational oncology target, MUC1*, present on approximately 80% of solid tumors. Its lead programs include MUC1*-targeted CAR T-cell therapies and antibody-drug conjugates (ADCs) for cancers like breast, lung, ovarian, and pancreatic. In parallel, the company has leveraged its discoveries in stem cell biology to develop the AlphaSTEM® platform, aimed at improving the generation and differentiation of induced pluripotent stem cells (iPSCs) for regenerative medicine applications.

OncologyRegenerative Medicine

Technology Platform

Platform based on the MUC1* growth factor receptor for cancer and the AlphaSTEM® system using NME7AB growth factor for naïve stem cell culture and differentiation.

Funding History

2
Total raised:$25.2M
Series A$25M
Grant$200K

Opportunities

Targeting MUC1* addresses approximately 80% of solid tumors, a vast unmet need where CAR T therapy has yet to succeed.
The AlphaSTEM® platform could become a critical enabling technology for the growing field of iPSC-derived regenerative medicines, creating a potential dual-revenue stream.

Risk Factors

The core scientific premise of targeting MUC1* remains unproven in human trials, carrying high clinical risk.
As a private, pre-revenue company, it faces significant financial risk and depends on raising capital to fund expensive cell therapy development.
It also competes with larger, well-funded entities in both oncology and stem cell tools.

Competitive Landscape

In solid tumor CAR T, Minerva competes with numerous biotechs targeting various antigens (e.g., HER2, MSLN, CLDN18.2). Its differentiation is the prevalence of the MUC1* target. In stem cell tools, it competes with companies like Thermo Fisher Scientific and STEMCELL Technologies that supply cell culture media and growth factors, requiring it to demonstrate superior performance with AlphaSTEM®.

More companies in Oncology (General) →More companies in United States →